-
Je něco špatně v tomto záznamu ?
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus, M. Baccarani, RT. Silver, C. Schiffer, JF. Apperley, F. Cervantes, RE. Clark, JE. Cortes, MW. Deininger, F. Guilhot, H. Hjorth-Hansen, TP. Hughes, JJWM. Janssen, HM. Kantarjian, DW. Kim, RA. Larson, JH. Lipton, FX. Mahon, J. Mayer,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- analýza přežití MeSH
- aniliny terapeutické užití MeSH
- antitumorózní látky terapeutické užití MeSH
- bcr-abl fúzové proteiny antagonisté a inhibitory genetika metabolismus MeSH
- chinoliny terapeutické užití MeSH
- chronická myeloidní leukemie diagnóza farmakoterapie genetika mortalita MeSH
- dasatinib terapeutické užití MeSH
- exprese genu MeSH
- imatinib mesylát terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- klinické rozhodování MeSH
- konsensuální konference jako téma MeSH
- kvalita života MeSH
- lidé MeSH
- management nemoci MeSH
- monitorování fyziologických funkcí MeSH
- naděje dožití trendy MeSH
- nitrily terapeutické užití MeSH
- pyrimidiny terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
3 Medizinische Klinik Medizinische Fakultät Mannheim Universität Heidelberg Mannheim Germany
Almazov National Research Centre St Petersburg Russian Federation
Amsterdam University Medical Center VUMC Amsterdam The Netherlands
Centre Hospitalier Universitaire de Poitiers Poitiers France
Centre Léon Bérard Lyon France
Department Clinical Medicine and Surgery University Federico Secondo Naples Italy
Department of Hematology Oncology Policlinico S Orsola Malpighi University of Bologna Bologna Italy
Department of Internal Medicine Masaryk University Hospital Brno Czech Republic
Department of Molecular and Clinical Cancer Medicine University of Liverpool Liverpool UK
Fred Hutchinson Cancer Center Seattle WA USA
Georgia Cancer Center Augusta University Augusta GA USA
Hammersmith Hospital Imperial College London UK
Hospital Clinic IDIBAPS Barcelona Spain
Hospital de la Princesa Madrid Spain
Huntsman Cancer Center Salt Lake City Salt Lake City UT USA
Institut Bergonie Université de Bordeaux Bordeaux France
Karmanos Cancer Center Detroit MI USA
Klinik für Innere Medizin 2 Universitätsklinikum Jena Germany
MD Anderson Cancer Center Houston TX USA
National Research Center for Hematology Moscow Russian Federation
Norwegian University of Science and Technology Trondheim Norway
South Australian Health and Medical Research Institute Adelaide SA Australia
St Mary´s Hematology Hospital The Catholic University Seoul Korea
Universitätsklinikum Leipzig Germany
University of Chicago Chicago IL USA
University of Lund Lund Sweden
University of Toronto Toronto Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025114
- 003
- CZ-PrNML
- 005
- 20201222153701.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-020-0776-2 $2 doi
- 035 __
- $a (PubMed)32127639
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hochhaus, A $u Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany. andreas.hochhaus@med.uni-jena.de.
- 245 10
- $a European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia / $c A. Hochhaus, M. Baccarani, RT. Silver, C. Schiffer, JF. Apperley, F. Cervantes, RE. Clark, JE. Cortes, MW. Deininger, F. Guilhot, H. Hjorth-Hansen, TP. Hughes, JJWM. Janssen, HM. Kantarjian, DW. Kim, RA. Larson, JH. Lipton, FX. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, JP. Radich, D. Rea, J. Richter, G. Rosti, P. Rousselot, G. Saglio, S. Saußele, S. Soverini, JL. Steegmann, A. Turkina, A. Zaritskey, R. Hehlmann,
- 520 9_
- $a The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
- 650 _2
- $a aniliny $x terapeutické užití $7 D000814
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a klinické rozhodování $7 D000066491
- 650 _2
- $a konsensuální konference jako téma $7 D003245
- 650 _2
- $a dasatinib $x terapeutické užití $7 D000069439
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a bcr-abl fúzové proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016044
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x terapeutické užití $7 D000068877
- 650 _2
- $a chronická myeloidní leukemie $x diagnóza $x farmakoterapie $x genetika $x mortalita $7 D015464
- 650 _2
- $a naděje dožití $x trendy $7 D008017
- 650 _2
- $a monitorování fyziologických funkcí $7 D008991
- 650 _2
- $a nitrily $x terapeutické užití $7 D009570
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a chinoliny $x terapeutické užití $7 D011804
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Baccarani, M $u Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
- 700 1_
- $a Silver, R T $u Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Schiffer, C $u Karmanos Cancer Center, Detroit, MI, USA.
- 700 1_
- $a Apperley, J F $u Hammersmith Hospital, Imperial College, London, UK.
- 700 1_
- $a Cervantes, F $u Hospital Clinic IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Clark, R E $u Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
- 700 1_
- $a Cortes, J E $u Georgia Cancer Center, Augusta University, Augusta, GA, USA.
- 700 1_
- $a Deininger, M W $u Huntsman Cancer Center Salt Lake City, Salt Lake City, UT, USA.
- 700 1_
- $a Guilhot, F $u Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
- 700 1_
- $a Hjorth-Hansen, H $u Norwegian University of Science and Technology, Trondheim, Norway.
- 700 1_
- $a Hughes, T P $u South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
- 700 1_
- $a Janssen, J J W M $u Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands.
- 700 1_
- $a Kantarjian, H M $u MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Kim, D W $u St. Mary´s Hematology Hospital, The Catholic University, Seoul, Korea.
- 700 1_
- $a Larson, R A $u University of Chicago, Chicago, IL, USA.
- 700 1_
- $a Lipton, J H $u University of Toronto, Toronto, Canada.
- 700 1_
- $a Mahon, F X $u Institut Bergonie, Université de Bordeaux, Bordeaux, France.
- 700 1_
- $a Mayer, J $u Department of Internal Medicine, Masaryk University Hospital, Brno, Czech Republic.
- 700 1_
- $a Nicolini, F $u Centre Léon Bérard, Lyon, France.
- 700 1_
- $a Niederwieser, D $u Universitätsklinikum, Leipzig, Germany.
- 700 1_
- $a Pane, F $u Department Clinical Medicine and Surgery, University Federico Secondo, Naples, Italy.
- 700 1_
- $a Radich, J P $u Fred Hutchinson Cancer Center, Seattle, WA, USA.
- 700 1_
- $a Rea, D $u Hôpital St. Louis, Paris, France.
- 700 1_
- $a Richter, J $u University of Lund, Lund, Sweden.
- 700 1_
- $a Rosti, G $u Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
- 700 1_
- $a Rousselot, P $u Centre Hospitalier de Versailles, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France.
- 700 1_
- $a Saglio, G $u University of Turin, Turin, Italy.
- 700 1_
- $a Saußele, S $u III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Soverini, S $u Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
- 700 1_
- $a Steegmann, J L $u Hospital de la Princesa, Madrid, Spain.
- 700 1_
- $a Turkina, A $u National Research Center for Hematology, Moscow, Russian Federation.
- 700 1_
- $a Zaritskey, A $u Almazov National Research Centre, St. Petersburg, Russian Federation.
- 700 1_
- $a Hehlmann, R $u III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany. hehlmann.eln@gmail.com. ELN Foundation, Weinheim, Germany. hehlmann.eln@gmail.com.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 4 (2020), s. 966-984
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32127639 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153657 $b ABA008
- 999 __
- $a ok $b bmc $g 1599259 $s 1115800
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 4 $d 966-984 $e 20200303 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20201125
